SELLAS Announces Enrollment of First Patient in Phase 1 Trial of Galinpepimut-S (GPS) in Combination with Nivolumab (Opdivo®) in Patients with Malignant Pleural Mesothelioma (MPM)
February 11, 2020 08:30 ET
|
SELLAS Life Sciences Group
NEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Names Dragan Cicic, MD, as Senior Vice President, Clinical Development
February 10, 2020 08:45 ET
|
SELLAS Life Sciences Group
NEW YORK, Feb. 10, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Highlights Clinical Development Progress and Expected 2020 Milestones
January 13, 2020 08:30 ET
|
SELLAS Life Sciences Group
- Phase 3 Galinpepimut-S (GPS) Acute Myeloid Leukemia (AML) Study Open for Enrollment and Patient Screening Underway - - Regulatory Feedback Regarding Nelipepimut-S (NPS) in Triple...
SELLAS Announces Pricing of $6.5 Million Registered Direct Offering Priced At-The-Market
January 09, 2020 09:00 ET
|
SELLAS Life Sciences Group
NEW YORK, Jan. 09, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Commences Pivotal Phase 3 REGAL Study of Galinpepimut-S (GPS) in Patients with Acute Myeloid Leukemia (AML)
January 08, 2020 08:30 ET
|
SELLAS Life Sciences Group
-- Study Open for Enrollment and Patient Screening Underway -- NEW YORK, Jan. 08, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage...
SELLAS to Present at Biotech Showcase™
January 06, 2020 08:15 ET
|
SELLAS Life Sciences Group
NEW YORK, Jan. 06, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS to Present at the 12th Annual LD Micro Main Event
December 04, 2019 08:00 ET
|
SELLAS Life Sciences Group
NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2019 Financial Results
November 14, 2019 16:30 ET
|
SELLAS Life Sciences Group
- Phase 3 Registrational Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) on Track to Initiate by Year End - - Clinically Significant Follow-up Data from Phase 1 Trial Continues to...
SELLAS to Host R&D Investor Event on Galinpepimut-S (GPS) and the Next Generation of Cancer Immunotherapy
November 08, 2019 08:00 ET
|
SELLAS Life Sciences Group
NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel...
SELLAS Announces Reverse Stock Split
November 06, 2019 09:20 ET
|
SELLAS Life Sciences Group
NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel...